{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:44:43Z","timestamp":1791531883277,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40265-024-02035-2","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:02:08Z","timestamp":1715994128000},"page":"737-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Cefepime\/Enmetazobactam: First Approval"],"prefix":"10.1007","volume":"84","author":[{"given":"Susan J.","family":"Keam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"issue":"5","key":"2035_CR1","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/AAC.00105-19","volume":"63","author":"KM Papp-Wallace","year":"2019","unstructured":"Papp-Wallace KM, Bethel CR, Caillon J, et al. Beyond piperacillin-tazobactam: cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination. Antimicrob Agents Chemother. 2019;63(5):e00105-e119.","journal-title":"Antimicrob Agents Chemother"},{"key":"2035_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgar.2021.02.031","volume":"25","author":"A Belley","year":"2021","unstructured":"Belley A, Morrissey I, Hawser S, et al. Third-generation cephalosporin resistance in clinical isolates of Enterobacterales collected between 2016\u20132018 from USA and Europe: genotypic analysis of \u03b2-lactamases and comparative in vitro activity of cefepime\/enmetazobactam. J Glob Antimicrob Resist. 2021;25:93\u2013101.","journal-title":"J Glob Antimicrob Resist."},{"issue":"13","key":"2035_CR3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jama.2022.17034","volume":"328","author":"KS Kaye","year":"2022","unstructured":"Kaye KS, Belley A, Barth P, et al. Effect of cefepime\/enmetazobactam vs piperacillin\/tazobactam on clinical cure and microbiological eradication in patients with complicated urinary tract infection or acute pyelonephritis: a randomized clinical trial. JAMA. 2022;328(13):1304\u201314.","journal-title":"JAMA"},{"issue":"3","key":"2035_CR4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/jac\/dkaa511","volume":"76","author":"B Isler","year":"2021","unstructured":"Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother. 2021;76(3):550\u201360.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2035_CR5","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/cid\/ciaa373","volume":"72","author":"SS Magill","year":"2021","unstructured":"Magill SS, O\u2019Leary E, Ray SM, et al. Antimicrobial use in US hospitals: comparison of results from emerging infections program prevalence surveys, 2015 and 2011. Clin Infect Dis. 2021;72(10):1784\u201392.","journal-title":"Clin Infect Dis"},{"issue":"13","key":"2035_CR6","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1001\/jama.2022.15228","volume":"328","author":"SD Advani","year":"2022","unstructured":"Advani SD, Claeys K. Cefepime\/enmetazobactam for complicated urinary tract infections. JAMA. 2022;328(13):1299\u2013301.","journal-title":"JAMA"},{"issue":"2","key":"2035_CR7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01676-21","volume":"66","author":"JC V\u00e1zquez-Ucha","year":"2022","unstructured":"V\u00e1zquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-S\u00e1nchez P, et al. Assessment of activity and resistance mechanisms to cefepime in combination with the novel \u03b2-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a multicenter collection of carbapenemase-producing Enterobacterales. Antimicrob Agents Chemother. 2022;66(2): e0167621.","journal-title":"Antimicrob Agents Chemother"},{"key":"2035_CR8","unstructured":"European Medicines Agency. Cefepime\/enmetazobactam: EU prescribing information. 2024. https:\/\/www.ema.europa.eu\/. Accessed 11 Apr 2024."},{"key":"2035_CR9","unstructured":"Allecra Therapeutics. Cefepime\/enmetazobactam: US prescribing information. 2024. https:\/\/www.fda.gov\/. Accessed 26 Feb 2024."},{"key":"2035_CR10","unstructured":"Allecra Therapeutics. Allecra Therapeutics announces US FDA approval for EXBLIFEP\u00ae for the treatment of complicated urinary tract infections [media release]. 27 Feb 2024. https:\/\/www.allecra.com."},{"key":"2035_CR11","unstructured":"US Food & Drug Administration. Exblifep (cefepime and enmetazobactam): approval letter. 2024. https:\/\/www.fda.gov\/. Accessed 20 Mar 2024."},{"key":"2035_CR12","unstructured":"ADVANZ PHARMA Limited, Allecra Therapeutics. ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP\u00ae (cefepime\/enmetazobactam) for the treatment of severe infections [media release]. 27 Mar 2024. https:\/\/www.advanzpharma.com\/."},{"key":"2035_CR13","unstructured":"European Medicines Agency. Cefepime\/enmetazobactam: EU assessment report. 2024. https:\/\/www.ema.europa.eu\/. Accessed 11 Apr 2024."},{"key":"2035_CR14","unstructured":"Allecra Therapeutics. Allecra Therapeutics and ADVANZ PHARMA sign exclusive license and supply agreement for Allecra\u2019s antibiotic cefepime\/enmetazobactam in Europe [media release]. 13 Jan 2022. https:\/\/www.allecra.com."},{"key":"2035_CR15","unstructured":"Allecra Therapeutics GmbH, Shanghai Haini Pharmaceutical Co Ltd. Allecra Therapeutics and Shanghai Haini Pharmaceutical announce exclusive licensing agreement for cefepime\/enmetazobactam for Greater China [media release]. 21 Dec 2020. https:\/\/www.allecra.com\/."},{"key":"2035_CR16","unstructured":"Orchid Chemicals & Pharmaceuticals. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics [media release]. 18 Apr 2013. https:\/\/www.orchidpharma.com."},{"key":"2035_CR17","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/ph15040463","volume":"15","author":"L Principe","year":"2022","unstructured":"Principe L, Lupia T, Andriani L, et al. Microbiological, clinical, and PK\/PD features of the new anti-Gram-negative antibiotics: \u03b2-lactam\/\u03b2-lactamase inhibitors in combination and cefiderocol\u2014an all-inclusive guide for clinicians. Pharmaceuticals (Basel). 2022;15:463.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"2035_CR18","doi-asserted-by":"publisher","first-page":"e00514","DOI":"10.1128\/AAC.00514-19","volume":"63","author":"I Morrissey","year":"2019","unstructured":"Morrissey I, Magnet S, Hawser S, et al. In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from US and European hospitals during 2014\u20132015. Antimicrob Agents Chemother. 2019;63(7):e00514-e519.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2035_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105925","volume":"56","author":"L Tselepis","year":"2020","unstructured":"Tselepis L, Langley GW, Aboklaish AF, et al. In vitro efficacy of imipenem-relebactam and cefepime-AAI101 against a global collection of ESBL-positive and carbapenemase-producing Enterobacteriaceae. Int J Antimicrob Agents. 2020;56(1): 105925.","journal-title":"Int J Antimicrob Agents"},{"key":"2035_CR20","unstructured":"Hawser S, Morrissey I, Kothari N, et al. Influence of genotype on the activity of cefepime\/enmetazobactam against beta-lactam resistant Enterobacterales collected from Europe in 2019-2021 [abstract and poster no. P0097]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023."},{"issue":"8","key":"2035_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00926-21","volume":"65","author":"P Knechtle","year":"2021","unstructured":"Knechtle P, Shapiro S, Morrissey I, et al. Sigmoid Emax modeling to define the fixed concentration of enmetazobactam for MIC testing in combination with cefepime. Antimicrob Agents Chemother. 2021;65(8): e0092621.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2035_CR22","first-page":"S60","volume":"10","author":"A Belley","year":"2023","unstructured":"Belley A, Kothari N, Monti F, et al. Antibacterial activity of cefepime\/enmetazobactam and comparator agents against US enterobacterales clinical isolates collected from 2019\u20132021. Open Forum Infect Dis. 2023;10(Suppl 2):S60\u201370.","journal-title":"Open Forum Infect Dis"},{"key":"2035_CR23","unstructured":"Hawser S, Morrissey I, Kothari N, et al. Surveillance of cefepime\/enmetazobactam against European isolates of Enterobacterales collected between 2019 and 2021, including cephalosporin-resistant phenotypes [Abstract and poster no. P0289]. In: 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). 2023."},{"issue":"5","key":"2035_CR24","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1128\/AAC.00033-15","volume":"59","author":"JL Crandon","year":"2015","unstructured":"Crandon JL, Nicolau DP. In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae. Antimicrob Agents Chemother. 2015;59(5):2688\u201394.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2035_CR25","doi-asserted-by":"publisher","first-page":"e00078","DOI":"10.1128\/AAC.00078-20","volume":"64","author":"F Bernhard","year":"2020","unstructured":"Bernhard F, Odedra R, Sordello S, et al. Pharmacokinetics-pharmacodynamics of enmetazobactam combined with cefepime in a neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2020;64(6):e00078-e120.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2035_CR26","doi-asserted-by":"publisher","first-page":"e00180","DOI":"10.1128\/AAC.00180-20","volume":"64","author":"A Johnson","year":"2020","unstructured":"Johnson A, McEntee L, Farrington N, et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-\u03b2-lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e00180-e220.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2035_CR27","doi-asserted-by":"publisher","first-page":"e01468","DOI":"10.1128\/AAC.01468-20","volume":"65","author":"S Das","year":"2020","unstructured":"Das S, Fitzgerald R, Ullah A, et al. Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: towards new treatments for nosocomial pneumonia. Antimicrob Agents Chemother. 2020;65(1):e01468-e1520.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"2035_CR28","doi-asserted-by":"publisher","first-page":"S539","DOI":"10.1093\/ofid\/ofz360.1341","volume":"6","author":"Y Carmeli","year":"2019","unstructured":"Carmeli Y, Knechtle P, Hardenberg J, et al. A randomized phase 2 study of cefepime combined with the novel extended spectrum \u03b2-lactamase inhibitor enmetazobactam in hospitalized adults with complicated urinary tract infections (cUTI) including acute pyelonephritis (AP) [abstract no 1479]. OFID. 2019;6(Suppl 2):S539.","journal-title":"OFID."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02035-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02035-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T16:44:21Z","timestamp":1723221861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02035-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2035"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02035-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"16 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article the below mentioned reference has been updated","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10. Allecra Therapeutics. Allecra Therapeutics announces US FDA approval for EXBLIFEP\u00ae for the treatment of complicated urinary tract infections [media release]. 27 Feb 2024. HYPERLINK \"","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/www.allecra.com","URL":"https:\/\/doi.org\/https:\/\/www.allecra.com","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\".","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12. ADVANZ PHARMA Limited, Allecra Therapeutics. ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP\u00ae (cefepime\/enmetazobactam) for the treatment of severe infections [media release]. 27 Mar 2024.","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/www.advanzpharma.com\/","URL":"https:\/\/doi.org\/https:\/\/www.advanzpharma.com\/","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":".","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14. Allecra Therapeutics. Allecra Therapeutics and ADVANZ PHARMA sign exclusive license and supply agreement for Allecra\u2019s antibiotic cefepime\/enmetazobactam in Europe [media release]. 13 Jan 2022. HYPERLINK \"","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/www.allecra.com\/","URL":"https:\/\/doi.org\/https:\/\/www.allecra.com\/","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\".","order":14,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15. Allecra Therapeutics GmbH, Shanghai Haini Pharmaceutical Co Ltd. Allecra Therapeutics and Shanghai Haini Pharmaceutical announce exclusive licensing agreement for cefepime\/enmetazobactam for Greater China [media release]. 21 Dec 2020. HYPERLINK \"","order":15,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/www.allecra.com\/","URL":"https:\/\/doi.org\/https:\/\/www.allecra.com\/","order":16,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"\".","order":17,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16. Orchid Chemicals & Pharmaceuticals. Orchid enters into strategic partnership with Allecra Therapeutics for development of novel antibiotics [media release]. 18 Apr 2013. HYPERLINK \"","order":18,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/www.orchidpharma.com\/","URL":"https:\/\/doi.org\/https:\/\/www.orchidpharma.com\/","order":19,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":".","order":20,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Susan J. Keam is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}